BioSpace News Archive

Free online resource provides best practices businesses and schools can implement to improve indoor air quality

ARUP Laboratories announced that it now offers testing to detect the virus that causes COVID-19 using saliva specimens.

The Medical Device Innovation Consortium (MDIC) has announced the release of Best Practices for Communicating Benefit, Risk, and Uncertainty for Medical Devices.

Omeros Corporation announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, announced that the company will present at the following virtual investor conferences in September.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License Application (BLA) to support product approval of SER-109 for recurrent C. difficile infection (CDI). After obtaining highly statistically significant topline Phase 3 ECOSP

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that management will be participating in two upcoming investor conferences.

This collaboration combines Click Therapeutics’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in clinical development of treatments for neuropsychiatric diseases, furthering Boehringer Ingelheim’s commitment to exploring digital innovations to benefit patients with unmet medical needs

-- Brings expertise and leadership in scaling engineering and digital tools throughout her career as a tech entrepreneur --

VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL’s study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting . Data show that VBL’s anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolate